Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...

A Chinese-backed construction firm is under investigation after a 33-storey skyscraper collapsed in Bangkok during Myanmar's ...

The 94-year-old investor has seen more cycles than almost anyone alive. His moves are rarely impulsive and often signal ...